The high risk of bone involvement in cases of hormone-refractory prostate cancer has ... phase II trial of the alpha-emitter radium-223 (223 Ra) for the treatment of these patients.

A recent Phase III study evaluated radium-223 and best supportive care ... in addressing the primary metastatic site for most prostate cancer patients. [72] A better understanding of the bone ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... an α-emitter (radium-223), the bone resorption-targeting drug denosumab and an immunotherapy ...

A renewed interest in radiopharmaceuticals has led to ground-breaking research and improved outcomes in patients with prostate cancer ... showed that adding radium-223 to treatment with ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...

Depending on clinical context, radium‐223 is appropriate both ... “We now have several biomarkers to guide therapy in advanced prostate cancer such as homologous recombination DNA repair ...

The data and analysis firm wrote that while the treatment brought ... the first RLT approved for prostate cancer -- that goes ...

More Than 20 Alpha Therapies Are In Clinical Trials Says KUICK RESEARCH In Recent PublicationDelhi, Jan. 29, 2025 (GLOBE ...